Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

SLS

SELLAS Life Sciences Group Inc

Mar 20 • 04:00PM ET

4.76

-0.44 -8.46 %

Healthcare • Biotechnology • USA • NASD

Peers: TGTX KPTI IMMP AFMD ADAP BCRX ACET AVDL TLSA

| Held by: VTI IWM VXF IWO VTWO VFMO IWC ITOT VTWG CANC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.25	Insider Own	1.60%	Shs Outstand	153.10M	Perf Week	-11.36%
Market Cap	678.03M	Forward P/E	-	EPS next Y	-0.17	Insider Trans	2.86%	Shs Float	140.17M	Perf Month	17.82%
Enterprise Value	607.14M	PEG	-	EPS next Q	-0.06	Inst Own	29.58%	Short Float	35.05%	Perf Quarter	125.59%
Income	-26.86M	P/S	-	EPS this Y	-26.67%	Inst Trans	1.25%	Short Ratio	5.50	Perf Half Y	195.65%
Sales	0.00M	P/B	10.28	EPS next Y	46.32%	ROA	-54.84%	Short Interest	49.13M	Perf YTD	26.26%
Book/sh	0.46	P/C	9.43	EPS next 5Y	-	ROE	-66.88%	52W High	6.14 -22.48%	Perf Year	293.39%
Cash/sh	0.50	P/FCF	-	EPS past 3/5Y	51.28% 34.92%	ROIC	-37.66%	52W Low	0.95 400.21%	Perf 3Y	271.88%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.74% 10.78%	Perf 5Y	-55.18%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	54.32%	Oper. Margin	-	ATR (14)	0.50	Perf 10Y	-99.98%
Dividend Ex-Date	Mar 24, 2011	Quick Ratio	10.72	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.21	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.72	EPS Q/Q	45.12%	SMA20	-7.86%	Beta	2.15	Target Price	8.67
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	7.18%	Rel Volume	3.27	Prev Close	5.20
Employees	13	LT Debt/Eq	0.01	Earnings	Mar 19 AMC	SMA200	87.23%	Avg Volume	8.93M	Price	4.76
IPO	Mar 12, 2008	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.01% -	Trades		Volume	29,235,430	Change	-8.46%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-21-21	Initiated	Cantor Fitzgerald	Overweight	$18
Nov-01-18	Initiated	Oppenheimer	Outperform
Apr-02-18	Initiated	H.C. Wainwright	Buy	$11
Mar-19-18	Upgrade	Maxim Group	Hold → Buy	$13

Mar-19-26 04:05PM	SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +5.05% -8.46%
Mar-17-26 04:30PM	SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference (GlobeNewswire) -5.97%
Mar-12-26 08:35AM	SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009 (GlobeNewswire) -8.21%
Mar-04-26 12:59PM	What's Going With SELLAS Life Sciences Stock On Wednesday? (Benzinga)
Jan-14-26 08:30AM	SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe (GlobeNewswire)
08:35AM	Loading…
Dec-29-25 08:35AM	SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) (GlobeNewswire) +16.72%
Dec-07-25 06:00PM	SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 (GlobeNewswire)
Dec-04-25 12:20PM	Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (PR Newswire) +12.99%
Nov-12-25 04:05PM	SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-03-25 09:00AM	SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-29-25 11:57AM	Sellas Life Sciences Group Inc. (SLS) Advances Cancer Pipeline with $31M Funding and Upcoming R&D Showcase (Insider Monkey)
Oct-27-25 08:30AM	SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds (GlobeNewswire)
Oct-22-25 09:00AM	SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum (GlobeNewswire)
Oct-13-25 08:00AM	SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025 (GlobeNewswire)
Sep-30-25 08:30AM	SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update (GlobeNewswire)
08:30AM	Loading…
Sep-11-25 08:30AM	SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds (GlobeNewswire)
Aug-12-25 04:05PM	SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-25 08:30AM	SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification (GlobeNewswire)
Jul-31-25 07:02PM	SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised) (Zacks)
Jul-16-25 06:51PM	Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities (PR Newswire)
08:02AM	SELLAS CDK9 inhibitor to advance after exceeding expectations in AML (Clinical Trials Arena)
Jul-15-25 07:45AM	SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study (GlobeNewswire)
Jul-07-25 08:45AM	SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board (GlobeNewswire)
Jun-24-25 12:52PM	Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices (PR Newswire)
08:00AM	SELLAS Life Sciences to be Added to Russell 3000 and Russell 2000 Indexes (GlobeNewswire)
Jun-23-25 12:00PM	Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +11.04%
Jun-05-25 08:45AM	SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts (GlobeNewswire)
Jun-02-25 08:00AM	SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting (GlobeNewswire) -7.60%
May-21-25 06:00AM	Solaris Enters into US$200 Million Financing Agreements with Royal Gold to Advance the Warintza Project (GlobeNewswire) -12.37%
May-20-25 08:00AM	SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase (GlobeNewswire) +10.86%
08:45AM	Loading…
May-15-25 08:45AM	SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML (GlobeNewswire) +5.96%
May-13-25 04:05PM	SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -8.44% +7.09%
Apr-28-25 08:45AM	SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference (GlobeNewswire)
Apr-23-25 10:23AM	SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-08-25 08:45AM	SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML (GlobeNewswire)
Apr-05-25 12:37PM	Undercovered Dozen: Power Metals, Verses AI, TFS Financial, Nextdoor + (Seeking Alpha)
Mar-31-25 03:03PM	Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst (Seeking Alpha)
Mar-20-25 04:05PM	SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-27-25 10:10AM	Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire)
Feb-21-25 07:29AM	Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment (Clinical Trials Arena)
Feb-20-25 08:45AM	SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL (GlobeNewswire)
Jan-28-25 03:11PM	SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -17.02%
Jan-23-25 08:10AM	SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia (GlobeNewswire) -13.25%
Jan-08-25 08:20AM	SELLAS Announces Key Business Objectives for 2025 (GlobeNewswire) -9.49%
Jan-02-25 08:00AM	SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET (GlobeNewswire)
Dec-10-24 08:30AM	SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia (GlobeNewswire)
Dec-09-24 08:45AM	SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML (GlobeNewswire)
Nov-28-24 05:37AM	SELLAS announces data indicating key predictor of response to SLS009 in solid cancers (Clinical Trials Arena)
Nov-27-24 08:45AM	SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers (GlobeNewswire)
Nov-13-24 04:15PM	SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -5.93%
Nov-05-24 09:55AM	SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024 (GlobeNewswire)
Oct-15-24 08:45AM	SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia (GlobeNewswire)
Oct-10-24 04:05PM	SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-18-24 03:09PM	Sellas Life Sciences Group Inc (NASDAQ:SLS): A Bull Case Theory (Insider Monkey)
Aug-13-24 04:10PM	SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-06-24 08:45AM	SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas (GlobeNewswire)
Jul-31-24 08:30AM	SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market (GlobeNewswire) -7.20%
Jul-16-24 09:05AM	SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia (GlobeNewswire)
Jul-08-24 08:45AM	SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia (GlobeNewswire)
Jun-24-24 09:05AM	SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia (GlobeNewswire)
Jun-17-24 09:45AM	Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase (GlobeNewswire) -16.67%
09:05AM	SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia (GlobeNewswire)
Jun-10-24 08:40AM	SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML (GlobeNewswire)
May-14-24 10:54PM	SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q1 2024 (InvestorPlace) +7.30%
04:05PM	SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-01-24 08:35AM	SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level (GlobeNewswire)
Apr-29-24 08:45AM	SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study (GlobeNewswire) -17.12%
Mar-28-24 10:54PM	SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q4 2023 (InvestorPlace) +5.94%
04:05PM	SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:00AM	GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib) Treating Diffuse Large B Cell Lymphoma (PR Newswire)
Mar-26-24 07:35AM	SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study (GlobeNewswire)
Mar-19-24 04:05PM	SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
08:47AM	SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET (GlobeNewswire)
Mar-15-24 09:00AM	SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -29.03%
Mar-08-24 08:00AM	SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships (GlobeNewswire)
Mar-01-24 08:30AM	SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference (GlobeNewswire)
Feb-29-24 08:00AM	SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time (GlobeNewswire)
Feb-06-24 08:30AM	SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget (GlobeNewswire) +12.24%
Jan-25-24 08:45AM	SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference (GlobeNewswire)
Jan-11-24 06:00AM	GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia (PR Newswire)
Jan-10-24 11:30AM	SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate (Zacks)
Jan-09-24 08:30AM	SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients (GlobeNewswire)
Jan-04-24 09:01AM	SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering (GlobeNewswire) -35.77%
08:41AM	Why Is Sellas Life Sciences (SLS) Stock Down 25% Today? (InvestorPlace)
Jan-03-24 08:05PM	SELLAS Life Sciences Announces Proposed Public Offering (GlobeNewswire)
07:30AM	SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones (GlobeNewswire)
Dec-27-23 08:55AM	SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo in Advanced Malignant Pleural Mesothelioma (GlobeNewswire)
Dec-21-23 08:15AM	SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas (GlobeNewswire) -5.74%
Dec-14-23 08:30AM	SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia (GlobeNewswire) +14.15%
Dec-13-23 08:30AM	SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET (GlobeNewswire)
Dec-04-23 08:47AM	SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia (GlobeNewswire)
Nov-29-23 08:45AM	SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia (GlobeNewswire)
Nov-13-23 08:50AM	SELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls (CMC) Biologics License Application (BLA) Filing Strategy for Galinpepimut-S (GPS) (GlobeNewswire)
Nov-09-23 04:04PM	SELLAS Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 08:57AM	SELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting (GlobeNewswire)
Oct-31-23 08:05AM	SELLAS Life Sciences Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -16.37%
Oct-30-23 09:03AM	SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas (GlobeNewswire) +23.98%
Oct-17-23 08:45AM	SELLAS Life Sciences to Present Final Data from Phase 1/2 Study of Galinpepimut-S in Combination with Keytruda (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting (GlobeNewswire) -7.87%
Oct-16-23 08:45AM	SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia (GlobeNewswire)
Oct-12-23 04:05PM	SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia (GlobeNewswire) -10.42% +20.93%

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kalin Katherine Bach	Director	Nov 19 '25	Buy	1.59	63,400	100,806	104,400	Nov 21 08:45 AM
VAN NOSTRAND ROBERT L	Director	Jun 12 '25	Buy	1.48	10,000	14,800	20,400	Jun 13 08:00 AM
Wasman Jane	Director	May 30 '25	Buy	1.69	20,000	33,800	30,400	Jun 02 04:42 PM
Kalin Katherine Bach	Director	May 22 '25	Buy	1.80	20,000	36,000	41,000	May 22 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLS

SELLAS Life Sciences Group Inc

Upgrade your FINVIZ experience